Previous close | 0.2000 |
Open | 0.2000 |
Bid | 0.0000 |
Ask | 0.4000 |
Strike | 400.00 |
Expiry date | 2024-05-17 |
Day's range | 0.2000 - 0.2000 |
Contract range | N/A |
Volume | |
Open interest | 21 |
Novo Nordisk CEO Lars Jørgensen tells Yahoo Finance the company is confident about a robust GLP-1 sales year despite missing Wall Street estimates.
Earnings season continues to chug along, with results from many companies already delivered. And concerning positivity, all three of these companies' report fit the criteria, lifting outlooks following the results.
The Danish pharmaceutical firm, Europe’s most valuable company, said sales of the weight-loss drug jumped 106% in the first quarter.